title: Liposomes as nanovaccine delivery systems.
abstract: Since the discovery of liposomes by Alec Bangham in mid-1960s, these phospholipid vesicles have been widely used as pharmaceutical carriers. Liposomes have been extensively studied in the vaccine delivery field as a carrier and an immune stimulating agent. Liposomes are usually formulated as nanoparticles, mimicking the properties of pathogens, and have the ability to induce humoral and cell-mediated immune responses. In this review, we focused on modern nanotechnology-based approaches for the improvement of liposomal vaccine delivery systems. Topics such as size-dependent uptake, processing and activation of antigen presenting cells, targeting liposomes and route of administration are discussed.
authors.forename: Khairunnisa Abdul
authors.initials: KA
authors.lastname: Ghaffar
authors.forename: Ashwini Kumar
authors.initials: AK
authors.lastname: Giddam
authors.forename: Mehfuz
authors.initials: M
authors.lastname: Zaman
authors.forename: Mariusz
authors.initials: M
authors.lastname: Skwarczynski
authors.affiliation: School of Chemistry & Molecular Biosciences, University of Queensland, Chemistry Blg #68 St. Lucia, Queensland 4072, Australia. i.toth@uq.edu.au.
authors.forename: Istvan
authors.initials: I
authors.lastname: Toth
mesh_terms: D000818:Animals; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry*; D006801:Humans; D008081:Liposomes / Q000008:administration & dosage*; D050997:Nanomedicine; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry*; D014612:Vaccines / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology*
chemical_list: D004337:Drug Carriers; D008081:Liposomes; D014612:Vaccines